science
Revolution Medicines Presents Strong KRAS Drug Data and Preclinical Compound Insights
Revolution Medicines shared clinical trial success for its pancreatic cancer therapy last week and preclinical data on a new compound yesterday. The company also presented strong results for its KRAS drug at the AACR meeting on April 21, 2026. Additional biotech developments include Medicare's delay of an obesity drug coverage pilot and Kyverna Therapeutics' FDA submission plans.
ST
Substrate placeholder — needs reviewAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Revolution Medicines presented strong data on its KRAS drug on April 21, 2026, along with a glimpse of a novel class beyond it. The company showcased strong results for its KRAS drug at the AACR meeting on that date, as @statnews reported. Separately, Revolution Medicines, referred to as RevMed, presented clinical trial success data for its pancreatic cancer therapy at an event last week.
It followed up by presenting intriguing preclinical data on a new compound yesterday, which was April 21, 2026, given the current date of April 22, 2026. In related health policy news, Medicare delayed a pilot for covering obesity drugs, according to @statnews.
Kyverna Therapeutics plans to submit a cell therapy for stiff person syndrome for FDA approval, @statnews reported. On the political front, key GOP senators pushed back on a plan to cut NIH and reorganize HHS on April 21, 2026. The article detailing these events was written by Elaine Chen and published on April 22, 2026.
Elaine Chen is the National Biotech Reporter who covers biotech. She co-writes The Readout newsletter and co-hosts STAT’s weekly biotech podcast, The Readout Loud.
